Company Profiles

driven by the PitchBook Platform

Actavalon

Actavalon
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE (Announced)
$554k TOTAL AMOUNT RAISED
1 INVESTORS
Description

Developer of a single, broad spectrum drug designed to treat cancer. The company focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic, and colon cancer among others enabling doctors and physicians to treat cancer effectively.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
226 Jasmine Avenue
Corona del Mar, CA 92625
United States

+1 (949) 244-5684
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Actavalon’s full profile, request a free trial.

Actavalon Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 22-May-2017 $554k Announced Startup
2. Angel (individual) 18-Apr-2017 0000 00000 Completed Startup
1. Angel (individual) 07-Dec-2015 $529k $529k Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Actavalon Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JLABS Accelerator/Incubator 000 0000 000000 0

Actavalon Executive Team (4)

Name Title Board
Seat
Contact
Info
Wesley Hatfield Ph.D Co-Founder, Board of Director, President & Chief Executive Officer
Ned Israelsen Chairman & President
Elena Dneprovskaia Ph.D Chief Scientific Officer
Van Haynie Secretary & Board Member

Actavalon Board Members (5)

Name Representing Role Since Contact
Info
Michael Egan Actavalon Board Member 000 0000
Ned Israelsen Actavalon Chairman & President 000 0000
Teague Egan Self Board Member 000 0000
Van Haynie Actavalon Secretary & Board Member 000 0000
Wesley Hatfield Ph.D Actavalon Co-Founder, Board of Director, President & Chief Executive Officer 000 0000